Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine

Chien-Chiao Huang1,3☯, Kung-Kai Kuo2☯, Ta-Chun Cheng1,4, Chih-Hung Chuang1,5, Chien-Han Kao1, Yuan-Chin Hsieh3, Kuang-Hung Cheng6, Jaw-Yuan Wang3,7, Chiu-Min Cheng8, Chien-Shu Chen9*, Tian-Lu Cheng1,3,5,6*

1 Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan, 2 Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 3 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 4 Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan, 5 Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, Taiwan, 6 Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan, 7 Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 8 Department of Aquaculture, National Kaohsiung Marine University, Kaohsiung, Taiwan, 9 School of Pharmacy, China Medical University, Taichung, Taiwan

☯ These authors contributed equally to this work.
* cschen7@mail.cmu.edu.tw (CSC); tlcheng@kmu.edu.tw (TLC)

Abstract

The development of effective adjuvant is the key factor to boost the immunogenicity of tumor cells as a tumor vaccine. In this study, we expressed membrane-bound granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-18 (IL-18) as adjuvants in tumor cells to stimulate immune response. B7 transmembrane domain fused GM-CSF and IL-18 was successfully expressed in the cell membrane and stimulated mouse splenocyte proliferation. Co-expression of GM-CSF and IL-18 reduced tumorigenesis (P<0.05) and enhanced tumor protective efficacy (P<0.05) significantly in comparison with GM-CSF alone. These results indicated that the combination of GM-CSF and IL-18 will enhance the immunogenicity of a cell-based anti-tumor vaccine. This membrane-bound approach can be applied to other cytokines for the development of novel vaccine strategies.

Introduction

A major obstacle in tumor cell vaccine technology is inefficient stimulation of an immune response to induce anti-tumor effects. The co-administration of cytokines is a possible approach for the enhancement of anti-tumor immunity. Various cytokines have been tested for their host immune stimulation activity for cancer treatment, such as IL-2, GM-CSF, and INF-α[1]. Among these, GM-CSF has been widely studied and has shown promising anti-tumor results in many tumor models, such as melanoma cells[2], bladder cancer cells[3], murine leukemia[4], etc. GVAX (Cell Genesys) is a tumor vaccine comprised of genetically modified tumor cells engineered to secrete GM-CSF. It has been studied in a number of cancer types in preclinical and clinical trials[5], and demonstrated promising results in both phase I and II clinical trials of pancreatic and prostate cancer patients [6–8]. However, a phase III
Membrane-Bound GM-CSF and IL-18 as a Tumor Vaccine Adjuvant

Competing Interests: The authors have declared that no competing interests exist.

trial of GVAX was prematurely terminated because of the inability to meet the survival advantages[9–10]. Thus, to enhance the stimulatory effects of GM-CSF might be important for further vaccine development.

The combination of GM-CSF and a second cytokine might be an effective approach to improve the anti-tumor response. GM-CSF is regarded to be ideal adjuvant owing to its potent activation of dendritic cells (DC) and myeloid progenitor maturation. GM-CSF secreting tumor vaccines have been reported to induce massive accumulation of DCs at the inoculated site and in turn to activate tumor specific T cells to induce an anti-tumor response[11–15]. A second cytokine aimed at stimulating lymphoid cells might be important to further augment the immune response. IL-18 has been reported to effectively enhance Th1 immunity and tumor protection in murine models[16–17]. In addition, IL-18 was also reported to enhance the proliferation and cytotoxic activity of both T cells and NK cells[18–22]. Thus, IL-18 may be a good candidate to enhance the effects of GM-CSF.

In this study, we co-expressed GM-CSF and IL-18 in colon carcinoma cells (CT26) and examined the anti-tumor effects compared with GM-CSF alone (Fig 1A). We first generated the membrane-bound GM-CSF and IL-18 by fusion with the B7 transmembrane domain and the protein expression level was determined by flow cytometry. The bioactivity of membrane-bound GM-CSF and IL-18 was confirmed by the stimulation of mouse spleen cell proliferation. The tumor inhibition and tumor protection effects of GM-CSF were then investigated with or without IL-18. The results suggested that IL-18 might enhance the therapeutic potency of GM-CSF. In addition, the flexibility of this membrane-bound platform may facilitate the development of novel vaccine strategies.

Materials and Methods

Cells and animals

The mouse colon carcinoma cell line CT26 and the retroviral packaging cell line GP2-293 were purchased from American Type Culture Collection (ATCC). The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% heat-inactivated bovine calf serum, 100 units/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich) at 37°C in a humidified atmosphere containing 5% CO₂. Balb/cByJNarl mice (6 to 12 weeks old) were obtained from the National Laboratory Animal Center, Taipei, Taiwan. In the end of experiments, mice were sacrificed by CO₂ asphyxiation. All animal experiments were carried out in accordance with institutional guidelines and approved by the Animal Care and Use Committee of the Kaohsiung Medical University, Kaohsiung, Taiwan.

Construction and establishment of membrane-bound cytokine IL-18 and GM-CSF expressing CT26 cells

The precise cDNA sequence of murine IL-18 or GM-CSF followed by that of the B7 transmembrane domain was subcloned into the retroviral vector pLNCX (BD Biosciences, San Diego, USA) using a standard procedure (Fig 1B). Recombinant retroviral particles were packaged by co-transfection of pVSVG with pLNCX constructs into GP2-293 cells (Clontech, USA). After 48 hours, the harvested culture medium was filtered through a 0.22-μm syringe filter, followed by mixing with polybrene to 8 μg/mL. It was then added to CT26 colon carcinoma cells for virus infection. The stable CT26 cells were selected by G418 and were sorted by FACScaliber flow cytometer to establish CT26/IL-18, CT26/GM-CSF and CT26/GM-CSF/IL-18 clones.
Determination of expression of membrane-bound IL-18 and GM-CSF

The transduced CT26 cells (CT26/IL-18, CT26/GM-CSF and CT26/GM-CSF/IL-18) were resuspended in a polystyrene tube (Falcon, USA) at concentration of $1 \times 10^6$ cells/ml in phosphate buffered saline (PBS). Cells were stained with 5 μg/ml mouse anti-HA antibody for 30 min, followed by 5 μg/ml FITC-conjugated goat anti-mouse IgG for 30 min. After extensive washing, the fluorescence of the cells was measured and sorted by a FACScaliber flow cytometer.

For double staining, $1 \times 10^6$ CT26/GM-CSF/IL-18 were first incubated with goat anti-mouse IL-18 IgG (Santa Cruz) and rat anti-mouse GM-CSF IgG (BioLegend) for 30 min. Then Donkey anti-goat IgG (L+H)-FITC (Jackson) and goat anti-rat IgG-PE (Jackson) were added sequentially for another two rounds of 30 min incubation. Three times of washes is needed between each incubation steps to remove the unbounded antibodies. After extensive washing, the fluorescence intensity was measured.

Determination of growth curves of membrane-bound cytokine IL-18 and GM-CSF expressing CT26 cells

For in vitro proliferation assay, transduced CT26 were seeded into 12-well cell plates at density of $5 \times 10^4$ cells in 1 ml culture media. The CT26 cells were harvested by mixture of 100 μl of 0.05% trypsin contained PBS, and then added with 900 μl 10% BCS contained DMEM. The number of viable cells of each group was counted with the hemocytometer every twenty-four hours. Independent experiments were repeated three times.
Splenocyte proliferation assay for the bioactivity of membrane-bound IL-18 and/or GM-CSF

CT26 cells were suspended in PBS at a concentration of 1×10⁶ cells/ml and continuously freeze-thawed 5 times in liquid nitrogen and a water bath at 37°C. Balb/C mice were injected i.p. with 50μl of prepared CT26, followed by a second injection 7 days after the first injection. 10 days after the first immunization, mice were sacrificed by CO₂ before the spleens were harvested. Spleens were mashed and filtered through a cell strainer, followed by treatment with ACK lysis buffer for RBC removal. After extensive washing, 1×10⁵ splenocytes were seeded in 96 well plates containing 200 μl medium per well. After co-incubation with 1×10⁴ irradiated transduced CT26 cells, ATPliTE luminescence assay (PerkinElmer) was performed at the indicated time point according to manufacturer’s instructions.

Determination of the tumorigenicity of IL-18 and/or GM-CSF-expressing CT26 cells

Transduced CT26 cells were washed 5 times in PBS before injection. The CT26 cells were suspended at the indicated concentrations and injected with 0.1 ml PBS. A group of BALB/c (n = 5) mice were injected s.c. in the right hind leg with 1×10⁶ cells of either transduced or mock-transduced CT26 cells (CT26/IL-18, CT26/GM-CSF, and CT26/GM-CSF/IL-18). Tumor volume (length × width × height × 0.5) was estimated from tumor-bearing mice every 3 or 4 days after injection. Mice were sacrificed by CO₂ asphyxiation when tumors reached a maximal size of 2,000 mm³.

Determination of the protective effects of IL-18 and/or GM-CSF expressing CT26 cells

After suspension, transduced CT26 cells were washed 5 times in PBS before injection. The CT26 cells were suspended at the appropriate concentration (1×10⁷ cells/ml) in PBS, and then received 30 Gy (1 Gy = 100 rads) radiation before vaccination. A group of BALB/c mice (n = 5) were injected s.c. in the right hind leg with 1×10⁶ radiated cells of transduced or mock-transduced CT26 in 100 μl PBS. Ten days after tumor cell vaccination, mice were challenged by s.c. injection with 5×10⁵ mock-transduced CT26 cells in the left hind leg. Tumor volume (length × width × height × 0.5) and tumor-free survival rate was estimated every 3 or 4 days after challenge. Tumor-free survival rate of each group was calculated as the cumulative number of tumor-free mice per total number of mice. Of note, all the mice survived until the end of the assay. Independent experiments were repeated three times. Mice were sacrificed by CO₂ asphyxiation when tumors reached a maximal size of 2,000 mm³.

Statistical Analysis

Statistical analysis was performed by using Graphpad Prism V5 software. All data was analyzed for significance by using One-way ANOVA followed by Student’s Newman-Keuls test. Statistical significance of differences was considered when P value was <0.05.

Results

Establishment of IL-18 and/or GM-CSF stably expressing CT26 cells

To assess the effect of adding IL-18 to GM-CSF, membrane-bound GM-CSF and IL-18 expressing CT26 cells were established. The murine GM-CSF and IL-18 genes, flanked by HA and Myc tag, were subcloned into the upstream of the B7 transmembrane domain (B7 Membrane-Bound GM-CSF and IL-18 as a Tumor Vaccine Adjuvant
Tm) in the retroviral vector pLNCX (Fig 1B). pLNCX/GM-CSF, pLNCX/IL-18, and pLNCX/GM-CSF/IL-18 plasmids were transfected into packaging cells for virus production. The virus was then harvested and infected into CT26 cells for surface expression of cytokines. After the selection of G418, stable cytokine expressing cells, CT26/GM-CSF, CT26/IL-18, and CT26/GM-CSF/IL-18, were established. The expression of surface GM-CSF and IL-18 was examined by flow cytometry. CT26/GM-CSF, CT26/IL-18, and CT26/GM-CSF/IL-18 cells revealed strong fluorescence intensity compared with the negative control, and demonstrated membrane-bound GM-CSF and IL-18 was successfully expressed on the CT26 cells (Fig 2A–2C).

To determine whether the expression of membrane-bound GM-CSF and/or IL-18 impairs cell growth of CT26 cells, in vitro proliferation assay was conducted. As shown in Fig 2D and S1 Table, the growth curves of these transduced CT26 cell lines are quite similar. Very low amount of Trypan blue positive cells were observed (average 1–10 cells each observation), which indicated no abnormal cell death was occurred. These results revealed that membrane-bound GM-CSF and/or IL-18 do not impair the CT26 cell proliferation/survival in vitro.

Confirmations of the bioactivity of membrane-bound GM-CSF and IL-18 by splenocyte proliferation assay

Next, to determine the bioactivity of these membrane-bound cytokines, we assessed the effects of CT26/IL-18, CT26/GM-CSF, and CT26/GM-CSF/IL-18 on mouse splenocytes proliferation. Splenocytes were isolated from mice immunized with the repeated freeze-and-thawed CT26 cells. After co-incubation with CT26/GM-CSF, CT26/IL18, and CT26/GM-CSF/IL-18, cell number was calculated at the indicated time points (Fig 3 and S2 Table). Compared with the negative control, significant proliferative response was observed in all three membrane cytokine expressing CT26 cells. The number of splenocytes stimulated by CT26/GM-CSF and CT26/GM-CSF/IL-18 reached to 5–7×10^5 in 24 hours and was rapidly reduced after 48 hours. Similarly, splenocytes incubated with CT26/IL-18 increased to 4×10^4 cells in 24 hours, but quickly decreased after 24 hours. Compared with GM-CSF alone, no enhanced stimulation of cell proliferation was observed with co-expression of IL-18 and GM-CSF. This data confirmed the bioactivity of membrane-bound GM-CSF, IL-18, and GM-CSF and IL-18 co-expression.

Tumorigenesis of CT26/GM-CSF, CT26/IL-18, and CT26/GM-CSF/IL-18 cells

To investigate the effects of IL-18 on GM-CSF on tumorigenesis, tumor growth of membrane-bound cytokine expressing CT26 cells was examined in a mouse model. CT26/GM-CSF, CT26/IL18, and CT26/GM-CSF/IL-18 cells (1 ×10^6 of each) were inoculated subcutaneously into Balb/C mice, and tumor volume was monitored from tumor-bearing mice every 3 or 4 days. As shown in Fig 4 and S3 Table, membrane-bound GM-CSF reduced the growth of CT26 tumor cells in comparison with control cells. Co-expression of membrane-bound IL-18 and GM-CSF significantly enhanced the tumor inhibitory effects of GM-CSF (P<0.05). Membrane-bound IL-18 alone had no effect on tumor formation, but an enhanced anti-tumor response was observed when it was combined with GM-CSF.

Tumor protective effects of CT26/GM-CSF, CT26/IL-18, and CT26/GM-CSF/IL-18 in vivo

To assess the effects of membrane-bound IL-18 and GM-CSF on systemic tumor protection, mice were re-challenged with mock-transduced CT26 after immunization with irradiated cytokine expressing CT26 cells. As shown in Fig 5A and S4 Table, vaccination of mock-transduced
Fig 2. Protein expression of membrane-bound GM-CSF and IL-18. CT26 cells stably expressing GM-CSF (A) or IL-18 (B) were stained with mouse anti-HA antibody, followed by FITC-conjugated goat anti-mouse IgG for 30 min. Mock-transduced CT26 cells were used as a negative control (black). (C) CT26/GM-CSF/IL-18 was doubly stained by anti-GM-CSF and anti-IL-18 primary antibodies, followed by FITC and PE-conjugated secondary antibodies.
CT26 cells provided protective effects when re-challenged with parental tumor cells in the other leg ten days after vaccination. An enhanced effect was observed when vaccination with CT26/GM-CSF compared to mock-transduced CT26. In contrast, CT26/IL-18 revealed no tumor protection effects and showed a similar degree of tumor inhibition to PBS control. Importantly, CT26/GM-CSF/IL-18 reduced tumor growth significantly in comparison with CT26/GM-CSF (P<0.05). These results suggested that the anti-tumor immunity elicited by CT26/GM-CSF can act systemically and inhibit tumors at a distant site, and the protection effects of GM-CSF were further amplified when it was used in combination with IL-18. In the end of tumor protective assay, the tumor free survival rate of respective group also showed similar results, which is about 40% (CT26/GM-CSF/IL-18), 25% (CT26/GM-CSF), 15% (CT26), and less than 5% (CT26/IL-18 and PBS control) (Fig 5B and S5 Table). Taken together, these results indicated that IL-18 might be a good candidate as an adjuvant to enhance the tumor protective effects of GM-CSF.

Discussion

In this study we demonstrated that membrane-bound IL-18 may increase anti-tumor effects used in combination with GM-CSF. Co-expression of IL-18 significantly reduced tumor growth (P<0.05) and improved the tumor protective effects (P<0.05) when compared with GM-CSF alone. Based on these results, the co-expression of GM-CSF and IL-18 may revive the possibility that GM-CSF can be used clinically. Additionally, our membrane-bound approach had higher flexibility to be easily applied to various secreted cytokines and cancer models. Thus, we believe this strategy may be useful in the development of novel vaccines.

Compared with soluble cytokines, the use of membrane-bound cytokines as an adjuvant has various potential advantages. The expression of membrane-bound cytokines allows for local activation of immune response at the vaccination site rather than systemic activation, which might potentially be harmful to patients. In contrast, strategies that either combine soluble proteins as an adjuvant or genetically modify tumor cells for cytokine secretion face potential problems caused by non-specific binding[23]. Several side-effects caused by systemic

![Fig 3. Splenocyte proliferation assay for the bioactivity of membrane-bound IL-18 and/or GM-CSF.](https://doi.org/10.1371/journal.pone.0133470.g003)
administration have been reported. Faries and colleagues showed the adverse outcome when
GM-CSF was administered as an allogeneic whole-cell melanoma vaccine. Systemic recruit-
ment of eosinophils and basophils was observed and accompanied by a trend toward worse
survival[24]. In a study by Hazenberg and colleagues, soluble GM-CSF was tested to correct
granulocytopenia in patients with Felty’s syndrome. However, an unpredictable flare-up of
arthritis of all joints and highly elevated IL-6 circulation was observed [25]. Similarly, Campbell
and colleagues reported that GM-CSF exacerbated collagen-induced arthritis in a mouse
model[26]. Thus, a strategy to stimulate immune response locally and specifically at the vacci-
nation site may be important for vaccine safety. A previous study evaluated the anti-tumor
effects of soluble GM-CSF and IL-18 expressing Lewis lung cancer tumor cells LL/2[27], the
non-specific delivery problem might need to be solved. In this study, the co-expression of
membrane-bound GM-CSF and IL-18 enhanced anti-tumor immunity without the potential
risks of systemic toxicity of soluble cytokines. Thus, the use of membrane-bound cytokines spe-
cifically acting on immune cells that infiltrate at vaccination site may be beneficial for vaccine
safety.

In addition, the local activation of anti-tumor response promotes systemic immune protec-
tion specific to tumor cells [28]. Locally accumulated stimulatory cytokines have also been
reported to alter the tumor microenvironment, resulting in tumor reduction, and induction of
prolonged protective immunity [29–30]. Soluble cytokines are hard to accumulate using con-
ventional strategies. Using the membrane-bound strategy, cytokines were enriched on the cell
membrane and were longer-lasting, which may also enhance the immune response for a vac-
cine. Moreover, direct targeting of tumor-associated antigens (TAAs) to antigen presenting
cells (APC) is more likely to occur with enriched membrane-bound GM-CSF on tumor cells
and their receptors on DCs. Taken together, we believe that the expression of cytokines in a
locally specific and concentrated manner may be one key to the enhancement of adjuvant
effects. Pan and colleagues expressed membrane-bound IL-12 with the use of the B7-1 trans-
membrane and cytoplasmic domains. They demonstrated that membrane-bound IL-12 has the
advantage of minimizing circulatingIL-12 without compromising its antitumor efficacy [31].
Bozeman and colleagues used GPI to anchor IL-2 and IL-12 on the membrane of murine mam-
mary tumor cells as a tumor vaccine. Their results showed that these modified tumor cells
effectively induced protective immunity, inhibited the growth of distant tumors, and overcome
the immune suppressive microenvironment [29]. Thus, this membrane-bound strategy may
improve the therapeutic potency and reduce the nonspecific toxicities of traditional vaccine
adjuvants.
Fig 5. Protective effects of membrane-bound GM-CSF and IL-18, and GM-CSF/IL-18 expressing CT26 cells. (A) Groups of BALB/c mice (n = 5) were injected s.c. in the right hind leg with $1 \times 10^6$ transduced tumor cells. Ten days after tumor cell implantation, mice were challenged by s.c. injection with $5 \times 10^5$ mock-transduced CT26 cells in the left hind leg. Tumor volume ($\text{length} \times \text{width} \times \text{height} \times 0.5$) was estimated every 3 or 4 days after challenge. Independent experiments were repeated three times. (B) Tumor free survival rate was estimated simultaneously (n = 20). The tumor free survival rate of respective group is about 40% (CT26/GM-CSF/IL-18), 25% (CT26/GM-CSF), 15% (CT26), and less than 5% (CT26/IL-18 and PBS control)

doi:10.1371/journal.pone.0133470.g005
The selection of anchor protein for surface expression is important for protein stability. Several advantages of the B7 transmembrane domain to anchor the secreted protein have been reported. Liao and colleagues demonstrated that B7-containing AFP chimeric protein displayed a longer half-life (about 12.2 h) compared with other targeting domains including DAF (3.8 h), ASGPR (2.4 h), or PDGFR (1.6 h), and indicated that the B7 fused protein is stable and correctly folded. They also showed that AFP-B7 fusion protein was rapidly sorted to the cell surface and did not undergo endocytosis[32]. Our results also demonstrated that the B7 transmembrane domain fused cytokines were highly expressed on the cell membrane and remained bioactive. Thus, the B7 transmembrane domain may be a good target for the membrane-bound strategy. In addition, if needed, the protein expression level and ratio can be further adjusted to achieve the best efficacy by cell sorting techniques. Using this platform, membrane-bound cytokines can be changed rapidly for various vaccine strategies. Also, this strategy could be applied to other tumor models easily because of the stability and high expression rate of the B7 fused protein.

The diversity of TAAs is a major challenge in vaccine development. Because of the lack of knowledge of TAAs in most human cancers, the use of tumor cells as a broad antigen source is currently considered to be the most effective means of presenting antigens[33]. Whole-cell tumor vaccines have been investigated for more than 20 years in both animal models and in human clinical trials, and various advantages have been reported[34]. First, unknown or mutated tumor antigens can be targeted by tumor vaccines. Second, whole tumor cell vaccines have been reported to target to both the innate and adaptive immune system for a better immune response [5, 35–36]. In contrast, protein-based vaccines have been reported to induce a stronger response on the generation of CD4+ T cells, but not CD8+ T cells, which is not beneficial for tumor clearance[37]. The weak immunogenicity of single peptides and tumor immune evasion through antigen point mutation has also been mentioned previously[38]. Thus, we chose whole tumor cells as the major source of TAAs, to provide a higher efficacy and lower cost method to re-activate the immunogenicity of tumor cells. However, one limitation of whole tumor vaccine is the possibility of eliciting autoimmune or allergic responses in both tumor-associated and self-antigens exposed to immune cells at the same time.

In this study, we successfully enhanced the effects of GM-CSF on CT26 tumor cells by co-expression with membrane-bound IL-18. Recently, the enhanced anti-tumor effect was also reported on Lewis lung cancer cells LL/2 modified to co-express soluble GM-CSF and IL-18 as a tumor vaccine[27]. The mechanism was reported mainly to be dependent on CD4+ and CD8+ T cells. In our study, the anti-tumor mechanism of membrane-bound GM-CSF and IL-18 might be similar. Of note, our membrane-bound strategy revealed several advantages: (1) Membrane-bound approach minimized circulating cytokines without compromising its efficacy and lowered the risk of potential side-effects caused by non-specific binding of cytokines; (2) B7 fused protein is stable, expressed at high levels in the membrane, and less internalized. It will, therefore, provide longer-lasting and stronger stimulation to effector cells; (3) Protein expression level and ratio can be easily adjusted to provide optimal anti-tumor effects; (4) Both cytokines and tumor models are selectable and conveniently exchangeable. With such flexibility and stability, we believe that this platform is valuable for novel vaccine development and the revival of the GM-CSF vaccine in clinical trials.

Supporting Information
S1 Table. Determination of growth curves of membrane-bound cytokine IL-18 and GM-CSF expressing CT26 cells. Mock-transduced CT26, CT26/GM-CSF, CT26/IL-18, and CT26/GM-CSF/IL-18 cells were seeded into 12-well plates at the density of $5\times10^4$ cells per
The number of viable cells (Trypan Blue negative) was counted with the hemocytometer every twenty-four hours. Independent experiments were repeated three times.

(S2 Table) **S2 Table. Splenocyte proliferation assay for the bioactivity of membrane-bound IL-18 and/or GM-CSF.** Splenocytes were harvested from mock-transduced CT26 immunized Balb/C mice. 1×10⁵ splenocytes were cultured with 1×10⁴ CT26/IL-18, CT26/GM-CSF, and CT26/GM-CSF/IL-18 cells for the indicated times. ATPlite luminescence assay was performed to measure the splenocytes proliferation.

(S3 Table) **S3 Table. Tumorigenicity of membrane-bound GM-CSF, IL-18, and GM-CSF/IL-18 expressing CT26 cells.** Groups of (n = 5) BALB/c mice were injected with 1 ×10⁶ transduced tumor cells s.c. in the right hind leg. Tumor volume (length × width × height × 0.5) was collected from tumor-bearing mice every 3 or 4 days after injection.

(S4 Table) **S4 Table. Protective effects of membrane-bound GM-CSF and IL-18, and GM-CSF/IL-18 expressing CT26 cells.** Groups of BALB/c mice (n = 5) were injected s.c. in the right hind leg with 1 ×10⁶ transduced tumor cells. Ten days after tumor cell implantation, mice were challenged by s.c. injection with 5×10⁵ mock-transduced CT26 cells in the left hind leg. Tumor volume (length × width × height × 0.5) was estimated every 3 or 4 days after challenge.

(S5 Table) **S5 Table. Tumor free survival rate of tumor protective assay.** Groups of BALB/c mice (n = 20) were injected s.c. in the right hind leg with 1 ×10⁶ transduced tumor cells. Ten days after tumor cell implantation, mice were challenged by s.c. injection with 5×10⁵ mock-transduced CT26 cells in the left hind leg. Tumor volume (length × width × height × 0.5) was estimated every 3 or 4 days after challenge.

**Acknowledgments**
The authors thank the help from the Statistical Analysis Laboratory, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University.

**Author Contributions**
Conceived and designed the experiments: CCH CSC TLC. Performed the experiments: CCH KK TCC CHC CHK YCH. Analyzed the data: CCH KK CHK KHC JYW CMC. Wrote the paper: CCH.

**References**
1. Gajewski TF. Cancer immunotherapy. Molecular oncology. 2012; 6(2):242–50. Epub 2012/01/18. doi: 10.1016/j.molonc.2012.01.002 PMID: 22248437; PubMed Central PMCID: PMC3345039.
2. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539–43. Epub 1993/04/15. PMID: 8097319; PubMed Central PMCID: PMC46336.
3. Zhang X, Shi X, Li J, Hu Z, Zhou D, Gao J, et al. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. The Journal of urology. 2012; 187(3):1071–9. Epub 2012/01/24. doi: 10.1016/j.juro.2011.10.126 PMID: 22268013.
4. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood. 1998; 91(1):220–30. Epub 1998/02/07. PMID: 9414288.

5. Keenan BP, Jaffee EM. Whole cell vaccines—past progress and future strategies. Seminars in oncology. 2012; 39(3):276–86. Epub 2012/05/19. doi: 10.1053/j.seminoncol.2012.02.007 PMID: 22595050; PubMed Central PMCID: PMC3356993.

6. Jaffee EM, Hruban RH, Biedrzycki B, Laeru D, Schepers K, Sauter PR, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001; 19(1):145–56. Epub 2001/01/03. PMID: 11134207.

7. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Annals of surgery. 2011; 253(2):328–35. Epub 2011/01/11. doi: 10.1097/SLA.0b013e3181d271c PMID: 21217520; PubMed Central PMCID: PMC3085934.

8. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. 2010; 16(4):304–10. Epub 2010/08/10. doi: 10.1097/PPO.0b013e3181e33d3f PMID: 20693640; PubMed Central PMCID: PMC3086689.

9. Higano CS, Somer B, Curti B, Petrylak DP, Drake CG, et al. A phase III trial of GVAX immunotherapy for prostate cancer vs docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancer Symposium: Proc Am Soc Clin Oncol. 2009:Abstract # LBA150.

10. Small E, Demkow T, Gerritsen W, Rolland F, Hoskin P, Smith D, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancer Symposium: Proc Am Soc Clin Oncol 2009:Abstract #7.

11. Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. The Journal of biological chemistry. 1977; 252(6):1998–2003. Epub 1977/03/25. PMID: 3003777.

12. Cook AD, Braine EL, Hamilton JA. Stimulus-dependent requirement for granulocyte-macrophage colony-stimulating factor in inflammation. J Immunol. 2004; 173(7):4643–51. Epub 2004/09/24. PMID: 15383599.

13. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discovery medicine. 2010; 10(50):52–60. Epub 2010/07/31. PMID: 20670599; PubMed Central PMCID: PMC3086372.

14. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008; 8(7):533–44. Epub 2008/06/14. doi: 10.1038/nri2356 PMID: 18551128.

15. van Nieuwenhuijze A, Koenders M, Roeleveld D, Sleeman MA, van den Berg W, Wicks IP. GM-CSF as a therapeutic target in inflammatory diseases. Molecular immunology. 2013; 56(4):675–81. Epub 2013/09/22. doi: 10.1016/j.molimm.2013.05.002 PMID: 23933508.

16. Marshall DJ, Rudnick KA, McCarthy SG, Mateo LR, Harris MC, McAuley C, et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine. 2006; 24(3):244–53. Epub 2005/09/02. doi: 10.1016/j.vaccine.2005.07.087 PMID: 16135392.

17. Tse BW, Russell PJ, Lochner M, Forster I, Power CA. IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS One. 2011; 6(9):e24241. Epub 2011/09/22. doi: 10.1371/journal.pone.0024241 PMID: 21935389; PubMed Central PMCID: PMC3174151.

18. Tao D, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cellular immunology. 1996; 173(2):230–5. Epub 1996/11/01. doi: 10.1006/cimm.1996.0272 PMID: 8912881.

19. Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol. 1997; 158(4):1541–50. Epub 1997/02/15. PMID: 9029088.

20. Tomura M, Zhou XY, Maruo S, Ahn HJ, Hamaoka T, Okamura H, et al. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. J Immunol. 1998; 160(10):4738–46. Epub 1998/05/20. PMID: 9590219.

21. Tsutsui H, Nakanishi K, Matsu K, Higashino K, Okamura H, Miyazawa Y, et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol. 1996; 157(9):3967–73. Epub 1996/11/01. PMID: 8892629.
22. Iwai Y, Hemmi H, Mizenina O, Kuroda S, Suda K, Steinman RM. An IFN-gamma-IL-18 signaling loop accelerates memory CD8+ T cell proliferation. PLoS One. 2008; 3(6):e2404. Epub 2008/06/12. doi:10.1371/journal.pone.0002404 PMID: 18545704; PubMed Central PMCID: PMC2408965.

23. Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC. Vaccines and immunotherapeutics for the treatment of malignant disease. Clinical & developmental immunology. 2010; 2010:697158. Epub 2010/10/12. doi:10.1155/2010/697158 PMID: 20936120; PubMed Central PMCID: PMC2948924.

24. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(22):7029–35. Epub 2009/11/12. doi:10.1158/1078-0432.CCR-09-1540 PMID: 19903777; PubMed Central PMCID: PMC2920049.

25. Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Stern AC, Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood. 1989; 74(8):2769–70. Epub 1989/12/01. PMID: 2510837.

26. Campbell IK, Bandele A, Smith DA, Hamilton JA. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Annals of the rheumatic diseases. 1997; 56(6):364–8. Epub 1997/06/01. PMID:9227165; PubMed Central PMCID: PMC1752394.

27. Tian H, Shi G, Yang G, Zhang J, Li Y, Du T, et al. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC cancer. 2014; 14:48. Epub 2014/01/31. doi:10.1186/1471-2407-14-48 PMID: 24475975; PubMed Central PMCID: PMC3922726.

28. Tahara H, Zeh HJ 3rd, Storkus WJ, Pappo I, Watkins SC, Gubler U, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994; 54(1):182–9. Epub 1994/01/01. PMID:7903204.

29. Bozeman EN, Cimino-Mathews A, Machiah DK, Patel JM, Krishnamoorthy A, Tien L, et al. Expression of membrane anchored cytokines and B7-1 transmembrane domains on mammalian cells. Biotechnology and bioengineering. 2001; 73(4):313–23. Epub 2001/04/03. PMID:11283914.

30. Pan WY, Lo CH, Chen CC, Wu PY, Roffler SR, Shyue SK, et al. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol Ther. 2012; 20(5):927–37. Epub 2012/02/16. doi: 10.1038/mt.2012.10 PMID: 22334018; PubMed Central PMCID: PMC3345985.

31. Liao KW, Chou WC, Lo YC, Roffler SR. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnology and bioengineering. 2001; 73(4):313–23. Epub 2001/04/03. PMID:11283914.

32. Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, et al. Allogeneic tumor cell vaccines: The promise and limitations in clinical trials. Human vaccines & immunotherapeutics. 2013; 10(1). Epub 2013/09/26. PMID: 24064957.

33. Kim YS. Tumor Therapy Applying Membrane-bound Form of Cytokines. Immune network. 2009; 9(5):158–68. Epub 2010/02/17. doi: 10.4110/in.2009.9.5.158 PMID: 20157604; PubMed Central PMCID: PMC2816950.

34. Copier J, Dalgleish A. Overview of tumor cell-based vaccines. International reviews of immunology. 2006; 25(5–6):297–319. Epub 2006/12/16. doi: 10.1080/08830180600992472 PMID: 17169778.

35. van den Boorn JG, Hartman G. Turning tumors into vaccines: co-opting the innate immune system. Immunity. 2013; 39(1):27–37. Epub 2013/07/31. doi: 10.1016/j.immuni.2013.07.011 PMID: 23890061.

36. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Current opinion in genetics & development. 2008; 18(1):11–8. Epub 2008/03/01. doi: 10.1016/j.gde.2007.12.007 PMID: 18308558; PubMed Central PMCID: PMC2694903.

37. Sankar S, Nayanar SK, Balasubramanian S. Current trends in cancer vaccines—a bioinformatics perspective. Asian Pacific journal of cancer prevention: APJCP. 2013; 14(7):4041–7. Epub 2013/09/03. PMID: 23991949.